Novel brain-penetrant inhibitor of G9a methylase blocks Alzheimer’s disease proteopathology for precision medication

Current amyloid beta-targeting approaches for Alzheimer’s disease (AD) therapeutics only slow cognitive decline for small numbers of patients. This limited efficacy exists because AD is a multifactorial disease whose pathological mechanism(s) and diagnostic biomarkers are largely unknown. Here we re...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Xian, Xie, Ling, Sheehy, Ryan, Xiong, Yan, Muneer, Adil, Wrobel, John, Park, Kwang-Su, Liu, Jing, Velez, Julia, Luo, Yanjia, Li, Ya-Dong, Quintanilla, Luis, Li, Yongyi, Xu, Chongchong, Wen, Zhexing, Song, Juan, Jin, Jian, Deshmukh, Mohanish
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Journal Experts 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10690335/
https://www.ncbi.nlm.nih.gov/pubmed/38045363
http://dx.doi.org/10.21203/rs.3.rs-2743792/v1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10690335/
https://www.ncbi.nlm.nih.gov/pubmed/38045363
http://dx.doi.org/10.21203/rs.3.rs-2743792/v1

Ejemplares similares